NJ Flexi Cap Fund
The Scheme is seeks to generate long term capital appreciation by investing in equity and equity related instruments across market capitalizations.
Growthvine rating: 2/5 — ranked #38 of 56 in category.
Fund basics
| Category | Equity: Flexi Cap |
|---|
| NAV | ₹12.92 (as of 2026-11-13) |
|---|
| AUM | ₹2,572 Cr |
|---|
| Expense ratio | 1.70% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dhaval Patel |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Sharpe ratio | 0.16 |
|---|
| Standard deviation | 17.18% |
|---|
| Max drawdown | −28.39% |
|---|
| Alpha | -2.42 |
|---|
| Beta | 1.02 |
|---|
Over 5 years, captured 91.7% of Nifty 500's upside and 98.7% of its downside.
Market cap allocation
| Large cap | 50.1% |
|---|
| Mid cap | 33.1% |
|---|
| Small cap | 16.8% |
|---|
Concentration
| Top 5 holdings | 22.5% |
|---|
| Top 10 holdings | 39.6% |
|---|
| Total holdings | 52 |
|---|
| Index overlap | 21.7% |
|---|
| Active share | 78.3% |
|---|
Top holdings
- ICICI Bank Ltd. — 5.1%
- Torrent Pharmaceuticals Ltd. — 4.6%
- Marico Limited — 4.6%
- Dr. Lal Pathlabs Limited — 4.1%
- Britannia Industries Ltd. — 4.0%
- Page Industries Ltd. — 3.6%
- Dr. Reddys Laboratories Ltd. — 3.6%
- Bajaj Auto Limited — 3.4%
- Cipla Ltd. — 3.4%
- Alkem Laboratories Limited — 3.2%
Top sectors
- Pharma & Biotech — 20.4%
- Automobile — 13.2%
- Banking & Financial — 9.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −3.2% | Q4 (Bottom) | #46 of 50 |
| 2025 | −2.9% | Q4 (Bottom) | #38 of 43 |
| 2024 | 13.7% | Q4 (Bottom) | #38 of 42 |